Alixia
Targeting the Tumor Ecosystem to address cancer drug resistance.
San Francisco, United States · Founded 2022 · $2.1M raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2022
- Website
- alixia.com
- Total Funding
- $2.1M
- Last Round
- $1.8M Series AJul 2024
- Rounds
- 2
About
Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.
Summary
Alixia is a Biotech company based in San Francisco, United States, founded in 2022. It has raised $2.1M in total across 2 rounds, most recently a $1.8M Series A round in Jul 2024. Investors include ZAKA VC, Y Combinator Continuity Fund and Endless Frontier Labs.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...